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Background: Hematuria following prostate radiotherapy is a known toxicity that may adversely affect a patient’s
quality of life. Given the higher dose of radiation per fraction using stereotactic body radiation therapy (SBRT) there
is concern that post-SBRT hematuria would be more common than with alternative radiation therapy approaches.
Herein, we describe the incidence and severity of hematuria following stereotactic body radiation therapy (SBRT) for
prostate cancer at our institution.
Methods: Two hundred and eight consecutive patients with prostate cancer treated with SBRT monotherapy with
at least three years of follow-up were included in this retrospective analysis. Treatment was delivered using the
CyberKnife® (Accuray) to doses of 35–36.25 Gy in 5 fractions. Toxicities were scored using the CTCAE v.4. Hematuria
was counted at the highest grade it occurred in the acute and late setting for each patient. Cystoscopy findings
were retrospectively reviewed. Univariate and multivariate analyses were performed. Hematuria-associated bother
was assessed via the Expanded Prostate Index Composite (EPIC)-26.
Results: The median age was 69 years with a median prostate volume of 39 cc. With a median follow-up of 48 months,
38 patients (18.3%) experienced at least one episode of hematuria. Median time to hematuria was 13.5 months. In the
late period, there were three grade 3 events and five grade 2 events. There were no grade 4 or 5 events. The 3-year
actuarial incidence of late hematuria≥ grade 2 was 2.4%. On univariate analysis, prostate volume (p = 0.022) and history
of prior procedure(s) for benign prostatic hypertrophy (BPH) (p = 0.002) were significantly associated with hematuria.
On multivariate analysis, history of prior procedure(s) for BPH (p < 0.0001) and α1A antagonist use (p = 0.008) were
significantly associated with the development of hematuria.
Conclusions: SBRT for prostate cancer was well tolerated with hematuria rates comparable to other radiation
modalities. Patients factors associated with BPH, such as larger prostate volume, alpha antagonist usage, and prior
history of procedures for BPH are at increased risk for the development of hematuria.Background
Radiation-induced hematuria is common after prostate
cancer treatment due to the close proximity of the bladder
and urethra to the prostate [1]. However, the incidence of
clinically significant (≥ grade 2) late gross hematuria after
conventionally fractionated external beam radiation
therapy is generally < 5%. Hematuria commonly occurs* Correspondence: SPC9@georgetown.edu
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unless otherwise stated.within the first three years following treatment but may
occur many years later [2-4]. In addition, hematuria is a
common clinical problem even in those without a history
of radiation treatment [5,6] and can be caused by urinary
tract infections, urolithiasis, benign prostatic enlargement
(BPH) and urologic malignancy. As hematuria can be a
sign of serious genitourinary disease, the evaluation
includes cystoscopy and imaging of the upper urinary
tract. Approximately 20% of patients with gross hematuria
are found to have a tumor of the urinary tract [6].
The risk of radiation-induced hematuria is dependent
upon both the total radiation dose and the volume of thehis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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related factors such as utilization of brachytherapy
[8,9] or concurrent androgen deprivation therapy
[10] may impact the risk of hematuria. Patient char-
acteristics, such as a history of prior urethral procedures
[10-12] and/or chronic anticoagulation therapy may in-
crease an individual patient’s risk of clinically significant
hematuria [13]. Whether hypofrationated radiation
therapy is safe in these high risk populations is yet to
be explored.
Clinical data suggest that hypofractionated radiation
therapy may be radiobiologically favorable to smaller
fraction sizes in prostate cancer radiotherapy [14]. The
α/β for prostate cancer may be as low as 1.5 Gy [14]. If
the α/β for prostate cancer is less than 3 Gy, which is
generally the value accepted for late urinary complica-
tions, the linear-quadratic model predicts that delivering
large radiation fraction sizes will result in improved local
control with a similar rate of urinary complications. Early
data for high dose rate brachytherapy monotherapy
reveals that such regimens are effective without undue
urinary toxicity [15].
Stereotactic body radiation therapy (SBRT) is a rela-
tively new approach that is emerging as a standard
treatment option for prostate cancer [16,17]. SBRT
uses even larger daily fractions of radiation (7–9 Gy)
to take advantage of this postulated radiobiological
advantage. Emerging data suggest that this approach
may provide similar clinical outcomes as other radiation
modalities with high rates of biochemical control and
low rates of grade 3 and higher toxicities [16,17].
Based on patient preference for a shorter treatment
course, SBRT utilization is likely to increase as long as
toxicity is acceptable. Here, we present our institutional
hematuria rates following SBRT for clinically localized
prostate cancer.Figure 1 Treatment plan. (a) Axial T2-weighted MR image demonstrating
axial CT images demonstrating the prostate (red line). Isodose lines shown
prescription dose, blue line: 75% of the prescription dose, orange line; andMethods
Patient selection
Georgetown University Hospital established its Prostate
SBRT Program in 2006. As of December 2013, 700
prostate cancer patients have been treated with SBRT
alone (monotherapy) or as a boost after convention-
ally fractionated external beam radiation therapy. A
small subset of these patients also received androgen
deprivation therapy (ADT) at the discretion of the
treating radiation oncologist or the patient’s urologist.
At the inception of our program, a prospective database
was established to record baseline patient characteristics.
At each follow-up visit, toxicity and quality of life
data have also been prospectively collected and re-
corded. Patients eligible for this study were those who
had SBRT monotherapy with or without ADT for
clinically localized prostate cancer. Internal Review
Board (IRB) approval was obtained for retrospective
review of our database.
SBRT treatment planning and delivery
SBRT treatment planning and delivery were conducted
as previously described (Figure 1) [18,19]. Four gold
markers were placed into the prostate 5–7 days prior to
simulation. Patients were simulated with an empty bladder.
Fused computed tomography (CT) and magnetic resonance
(MR) images were used for treatment planning. The clinical
target volume (CTV) included the prostate and the
proximal seminal vesicles. Intrafraction image-guidance
was employed to minimize the required PTV treatment
margins [20]. The PTV equaled the CTV expanded 3 mm
posteriorly and 5 mm in all other dimensions. The prescrip-
tion dose was 35–36.25 Gy to the PTV delivered in five
fractions of 7–7.25 Gy corresponding to a tumor EQD2 of
approximately 85–90 Gy assuming an alpha/ beta ratio of
1.5. The prescription isodose line was limited to ≥ 75%,central simple prostatectomy defect (arrow). (b) Treatment planning
as follows: 115% of the prescription dose, pink line; 100% of the
50% of the prescription dose, green line.




Age (y/o) Median 69 (48–90)
Age ≤ 60 12.5% 26
60 < Age ≤ 70 46.2% 96
Age > 70 41.3% 86





CCI = 0 68.3% 142
CCI = 1 22.6% 47
CCI ≥ 2 9.1% 19
Body Mass Index (BMI) Median 27.34 (15.02-44.96)
BMI≥ 30 29.3% 61
Partner Status Married or Partnered 76.4% 159
Not Partnered 23.6% 49
Employment Status Working 47.6% 99
Not Working 52.4% 109
Median Prostate
Volume (cc)
Median 38.6 (11.6-138.7) cc 208
Baseline AUA Score Median 7 (0 – 34) 141
Procedure for BPH 11.5% 24
α1A inhibitor usage 27.4% 57
Anticoagulant usage 32.2% 67




SBRT Dose 36.25 Gy 87.5% 182
35 Gy 12.5% 26
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of the prescription dose. The bladder was contoured and
evaluated with dose-volume histogram analysis during
treatment planning using Multiplan (Accuray Inc.,
Sunnyvale, CA) inverse treatment planning. The empty
bladder volume receiving 37 Gy was limited to < 10 cc in
all patients. The bladder dose-volume histogram (DVH)
goals were < 40% bladder volume receiving 50% of the
prescribed dose and < 10% receiving 100% of the prescribed
dose. To minimize the risk of local recurrence, the dose to
the prostatic urethra was not constrained [21].
Follow-up and statistical analysis
Hematuria was prospectively documented at follow-up
visits using the National Cancer Institute (NCI)
Common Toxicity Criteria (CTC) version 4.0. Acute
hematuria was defined as experiencing toxicity within
3 months of radiation therapy. Late hematuria was
defined as occurring at least 3 months after delivery
of radiation therapy. If a hematuria episode occurred
at a time point falling between follow-ups, it was
counted at the later follow-up. Grade 1 represents
minimal bleeding not requiring medications for symptom
control. Grade 2 indicates hematuria requiring new
medication (i.e. finasteride, aminocaproic acid). Grade
3 indicates hematuria requiring surgical intervention
(i.e. coagulation, TURP). Hematuria evaluations were
performed at the discretion of the patient’s urologist [5]
and cystoscopy findings were retrospectively reviewed.
Patients completed the Expanded Prostate Cancer
Index Composite (EPIC)-26 [22] before treatment and
during routine follow-up visits one month after the
completion of SBRT, every 3 months for the first year
and then every 6 months for the second and third
years. Bother due to hematuria was assessed via question
4c of the EPIC-26 (How big a problem, if any, has bleeding
with urination been for you during the last four weeks?)
[22]. The responses were grouped into three clinically rele-
vant categories (no problem, very small-small problem and
moderate to big problem).
Categorical demographic and disease related factors such
as age, race, risk groups, procedures for benign prostate
hypertrophy (BPH) (yes or no), baseline AUA scores,
Charlson Cormobidity Index (CCI) at baseline, and anti-
coagulant usage (aspirin, clopidogrel, or warfarin) prior to
treatment (yes or no) were compared using Chi-square ana-
lysis between patients reported hematuria during follow-up
and those who did not. Multivariate analysis was performed
using Cox’s proportional hazard regression model. All
calculations were performed using SPSS v. 22 (IBM).
Results
From February 2008 to August 2011, 208 prostate
cancer patients were treated per our institutional SBRTmonotherapy protocol (Table 1). The median follow-up
was 48 months (range, 36–60). They were ethnically
diverse with 45.2% being of non-Caucasian ancestry and a
median age of 69 years (48–90). Comorbidities were com-
mon with 32.2% taking anticoagulants prior to treatment.
The median prostate volume was 39 cc (11.6-138.7),
27.4% of patients utilized alpha-antagonists prior to SBRT
and 11.5% had prior procedures for benign prostatic
hyperplasia (BPH). By D’Amico classification, 82 patients
were low-, 109 intermediate-, and 17 high-risk. Thirty
patients (14.4%) also received androgen deprivation
therapy. The majority of the patients (87.5%) were
treated with 36.25 Gy in five 7.25 Gy fractions.
Baseline hematuria was uncommon. A total of 38
(18.3%) patients reported at least one episode of hematuria
following SBRT. The median time to hematuria was
13.5 months (range, 5–22). Twenty nine patients reported
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and 9 patients reported multiple episodes. Eleven
(5.4% of all patients) patients reported acute bleeding
and 24 (11.8% of all patients) patients reported late
bleeding. In the acute setting, there were two grade 2
toxicities. In the late period, there were five grade 2
events and three grade 3 events. There were no grade
4 or 5 events anytime during follow-up. No patient
required a blood transfusion or hyperbaric oxygen.
The 3-year actuarial incidence of late hematuria ≥ grade 2
was 2.4%. Hematuria had resolved in 95% of patients by the
subsequent follow-up. Interestingly, of the grade 2–3
events, five patients had a history of transurethral resection
of the prostate (TURP) or similar procedure prior to SBRT.
On univariate analysis, prostate volume (p = 0.022) and
history of prior procedure(s) for BPH (p = 0.002) were sig-
nificantly associated with hematuria. On multivariate ana-
lysis, history of prior procedure(s) for BPH (p ≤ 0.0001) and
α1A antagonist use (p = 0.008) were significantly associated
with the development of hematuria (Table 2). No other
baseline patient characteristics were significantly associated
with hematuria following SBRT.
Nineteen patients had one or more cystoscopies during
the follow-up period. The median interval from completion
of SBRT to cystoscopy was 24 months (range, 5–42
months). Radiation was the causative factor in 11 (60%) of
these patients. The most common radiation associated
findings on cystoscopy were hyperemia of the bladder
neck/prostatic urethra (Table 3). Minor coagulation was
performed in 2 patients. Three patients were found to have
a bladder cancer at 18, 30, and 36 months after SBRT.
At baseline, 3% of our cohort reported some level of
annoyance due to hematuria; however, only one patient
felt it was a moderate to big problem (Table 4).
Hematuria bother increased following treatment andTable 2 Impact of patient characteristics and treatment







D’Amico’s Risk Groups 0.805 0.122
Prostate Volume 0.022† 0.081
Initial PSA 0.546 0.804
Androgen Deprivation Therapy 0.507 0.507
Procedure for BPH prior to RT 0.002† <0.0001*
Initial AUA 0.508 0.897
α1A Antagonist usage 0.082 0.008*
Charlson Comorbidity Index 0.787 0.101
Anticoagulant usage 0.321 0.435
†significant in univariate analysis, *significant in multivarariate analysis.peaked at 9 months post treatment with 2.7% of patients
reporting that it was a moderate to big problem (Table 4).
Hematuria bother declined quickly and returned to baseline
by three years after SBRT with 1.3% of men feeling that
their hematuria was a moderate to big problem three years
post-SBRT (Table 4).
Discussion
To our knowledge, this is the first study to report
cystoscopy findings and the incidence of hematuria
following SBRT monotherapy for prostate cancer.
Hematuria was uncommon at any time point and
transient in most instances. The prevalence of patient
reported hematuria peaked at 9 months and resolved
spontaneously without recurrence. Despite the high bio-
chemical equivalent dose delivered by SBRT in this series,
these results are similar to conventionally fractionated
EBRT and brachytherapy with published studies reporting
rates of hematuria that range from 2.6% - 14% [23-26,9].
The etiology of late hematuria following prostate cancer
radiation therapy is multi-factorial [27]. Urolithiasis,
benign prostatic enlargement (BPH) and urologic
malignancy were the most common non-radiation
associated causes in our patients. Previous studies have
also reported that hematuria due to radiation therapy is
associated with pretreatment factors related to BPH
such as a high AUA score, large prostate volume, and
pre-radiation TURP [28]. Our data also supports
these conclusions since history of a TURP or similar
procedure, α1A antagonist use, and increasing prostate
volume were significantly associated with the development
of post-radiation hematuria. One patient who experienced
a grade 3 hematuria had a history of benign prostatic
hypertrophy with a large prostate and two prior TURP
procedures prior to receiving SBRT [18].
It has been well documented that pre-treatment TURP,
especially if done very close to radiation, increases the
risk of other late urinary toxicities such as stricture and
incontinence [11,29,30]. This is thought to be caused by
devascularization of the urethra after TURP and the
lessened ability of the mucosa to repair sublethal radiation
damage [30]. In addition, the anatomy of the prostate
base is altered after a TURP resulting in broadening
of the base; therefore, the treatment volume at the
bladder interface may include a larger part of the
bladder neck in the PTV [29].
Patients in our study with hematuria secondary to
radiation, who underwent cystoscopy, often had some
degree of bladder neck and/or prostatic urethra edema
and hypervascularity supporting the above hypotheses.
These cystoscopy findings have also been observed in
patients with hematuria after prostate brachytherapy [25].
In an effort to decrease the incidence of bladder neck
and prostatic urethra pathology, we have reduced the
Table 3 Patients with hematuria who underwent cystoscopy




Cystoscopy finding Etiology of
hematuria
1 42 Hyperemic prostatic urethra; bleeding from
prostatic urethra
Radiation
2 18, 30, 36 Bladder cancer Bladder cancer
3 24 Hyperemic bladder neck Radiation
4 Yes 18 Necrotic tissue in TURP defect, hyperemic bladder neck Radiation
5 18 Normal
6 Yes Yes 12 Varices of the prostatic urethra Radiation
7 Yes 32 Hyperemic bladder neck Radiation
8 Yes Yes 5 Hyperemic prostatic urethra and bladder neck Radiation
9 Yes 11 Bleeding from prostatic urethra Radiation
10 Yes Yes 24 Hyperemic prostatic urethra and bladder neck Radiation
11 9, 24 Normal Kidney stone
12 30 Bladder cancer Bladder cancer
13 6, 18 Hyperemic bladder neck and bladder stone Bladder stone
14 15 Normal Kidney stone
15 36 Bladder cancer Bladder cancer
16 Yes 27 Normal
17 Yes Yes 3, 6, 9, 12 Necrotic tissue in TURP defect; hyperemic bladder
neck and prostatic urethra
Radiation
18 Yes 1, 3, 6, 9, 12, 18 hyperemic bladder neck; bleeding from prostatic urethra Radiation
19 Yes Yes 24 Normal Kidney stone
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[18]. It is expected, that with these modifications, the
risk of hematuria will decline.
Interestingly, in our study, we did not find an association
between anticoagulation usage and hematuria as pre-
viously reported by others [13]. One possible explan-
ation is that we also included aspirin (low or high dose),
along with clopidogrel and warfarin in the analysis,
whereas most only include the latter two. Aspirin,
especially low dose, may not predispose patients to
bleeding as strongly as warfarin or clopidogrel and
may explain the discrepancy.
In this study, the PTV included the prostate and
proximal seminal vesicles with margin regardless of
risk group, as do many [31-34]. This is in contrast to
the Radiation Therapy Oncology Group (RTOG), which
recommends inclusion of the prostate only with margin in
the PTV for low risk prostate cancer. How the inclusion ofTable 4 Hematuria bother following SBRT for prostate cancer (
Start 1 3 6
No Problem 96.6% 96.5% 97.0% 97.3%
Very Small-Small Problem 2.9% 2.5% 1.5% 2.1%
Moderate-Big Problem 0.5% 1.0% 2.0% 1.1%
Total N= 207 202 200 188the proximal seminal vesicles affects the risk of hematuria
is unknown. A prior publication has demonstrated that
increasing the volume of the seminal vesicles included in
the PTV would only have a moderate increase in normal
tissue complication probability (NTCP) [35].
Hematuria following prostate cancer treatment is also
a quality of life issue [36]. Bother is defined as the degree
of interference or annoyance caused by a symptom
[37,38]. In this series, moderate to severe bother with
hematuria was uncommon. During the first two years
following SBRT, 1-2% of men reported hematuria bother
as a moderate to big problem at any given follow-up.
This change is comparable to with conventionally frac-
tionated radiation therapy and brachytherapy [36,39].
Three patients were diagnosed with bladder tumors
(1.4% of patients) at a median time of 30 months. These
results are consistent with those reported following
conventionally fractionated external radiation therapypatient-reported responses to question 4c of the EPIC-26)
9 12 18 24 30 36
93.1% 96.1% 96.4% 97.2% 96.5% 97.5%
4.8% 2.8% 3.0% 2.8% 2.9% 1.3%
2.7% 1.7% 1.2% 0.6% 1.2% 1.3%
188 181 167 176 172 157
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tumors were discovered due to increased surveillance
and were unlikely caused by SBRT due to the short
interval to development from treatment. The cystoscopy
reports were available for two of the three patients. One
patient had a non-muscle invasive tumor of the right
lateral wall. The second patient developed recurrent
superficial papillary tumors throughout the bladder.
Nonetheless, our results emphasize the importance of
cancer screening in patients who report gross hematuria
following SBRT. Longer follow-up will be required to
identify the true incidence of SBRT-associated bladder
tumors.
Our study has several limitations. We present the
self-reported hematuria incidence. As most men did
not undergo regular urinalysis during follow-up, the
true incidence of post-SBRT hematuria may be under-
estimated in this study. Likewise, most hematuria
events were transient and associated bother may have been
missed due to the timing of questionnaire administration
[42]. Furthermore, only a subset of patients underwent
cystoscopy. Therefore, the cause of hematuria is not
known for all patients who reported it. In the future
we plan to present a DVH analysis examining the
association between urethral and bladder doses with
hematuria in patients where radiation was the causa-
tive factor on cystoscopy. It is also possible that the
cause of hematuria could differ between the acute and late
setting; however, due to the low number of patients with
isolated acute hematuria (n = 5) a meaningful statistical
analysis could not be performed. And lastly, the median
follow up in this group of patients is relatively short, and
additional hematuria events could potentially be seen with
longer follow up [3].Conclusions
SBRT for clinically localized prostate cancer was well
tolerated with hematuria rates comparable to conven-
tionally fractionated external radiotherapy and brachy-
therapy. Patients factors associated with BPH, such as
larger prostate volume, α1A antagonist use and prior
history of procedures for BPH are at increased risk
for the development of hematuria. Less than 5% of
men felt post-treatment hematuria was a moderate to big
problem at any time point during follow-up. These results
need to be confirmed with longer follow-up.
Abbreviations
ADT: Androgen deprivation therapy; CT: Computed tomography;
CTC: Common toxicity criteria; CTV: Clinical target volume; DVH: Dose-volume
histogram; EQD2: Equivalent dose in 2-Gy fractions; EPIC: Expanded prostate
index composite; GTV: Gross target volume; Gy: Gray; IMRT: Intensity modulated
radiation therapy; IRB: Internal review board; PTV: Planning target volume;
QoL: Quality of life; MR: Magnetic resonance; NCI: National Cancer Institute;
SD: Standard deviation; SBRT: Stereotactic body radiation therapy.Competing interests
SP Collins and BT Collins serve as clinical consultants to Accuray Inc. The
Department of Radiation Medicine at Georgetown University Hospital
receives a grant from Accuray to support a research coordinator. The other
authors declare that they have no competing interests.
Authors’ contributions
MG and LC are lead authors who participated in manuscript drafting,
table/figure creation, and manuscript revision. AB, RM JK, and TY aided in
data collection and table/figure creation. SL is the dosimetrist who
contributed dosimetric data and figures. BC, PK, SS, AD, and JL are senior
authors who aided in drafting the manuscript and manuscript revision. SC is
the corresponding author who initially developed the concept, drafted and
revised the manuscript. All authors read and approved the final manuscript.
Acknowledgements
This work was supported by the James and Theodore Pedas Family
Foundation and NIH Grant P30CA051008.
Author details
1Department of Radiation Oncology, University of Louisville, Louisville, USA.
2Department of Radiation Medicine, Georgetown University Hospital, 3800
Reservoir Road, N.W, Washington D.C 20007, USA. 3Department of Urology,
Georgetown University Hospital, Washington, USA. 4Department of
Radiology, Georgetown University Hospital, Washington, USA.
Received: 13 October 2014 Accepted: 4 February 2015
References
1. Marks LB, Carroll PR, Dugan TC, Anscher MS. The response of the urinary
bladder, urethra, and ureter to radiation and chemotherapy. Int J Radiat
Oncol Biol Phys. 1995;31:1257–80.
2. Mathieu R, Arango JD, Beckendorf V, Delobel JB, Messai T, Chira C, et al.
Nomograms to predict late urinary toxicity after prostate cancer radiotherapy.
World J Urol. 2014;32:743–51.
3. Eifel PJ, Levenback C, Wharton JT, Oswald MJ. Time course and incidence of
late complications in patients treated with radiation therapy for FIGO stage
IB carcinoma of the uterine cervix. Int J Radiat Oncol Biol Phys.
1995;32:1289–300.
4. Lawton CA, Won M, Pilepich MV, Asbell SO, Shipley WU, Hanks GE, et al.
Long-term treatment sequelae following external beam irradiation for
adenocarcinoma of the prostate: analysis of RTOG studies 7506 and 7706.
Int J Radiat Oncol Biol Phys. 1991;21:935–9.
5. Margulis V, Sagalowsky AI. Assessment of hematuria. Med Clin North Am.
2011;95:153–9.
6. van der Molen AJ, Hovius MC. Hematuria: a problem-based imaging algorithm
illustrating the recent Dutch guidelines on hematuria. AJR Am J Roentgenol.
2012;198:1256–65.
7. Viswanathan AN, Yorke ED, Marks LB, Eifel PJ, Shipley WU. Radiation
dose-volume effects of the urinary bladder. Int J Radiat Oncol Biol Phys.
2010;76:S116–22.
8. Leapman MS, Hall SJ, Stone NN, Stock RG. Haematuria after prostate
brachytherapy. BJU Int. 2013;111:E319–24.
9. Buckstein M, Carpenter TJ, Stone NN, Stock RG. Long-term outcomes and
toxicity in patients treated with brachytherapy for prostate adenocarcinoma
younger than 60 years of age at treatment with minimum 10 years of
follow-up. Urology. 2013;81:364–8.
10. Zapatero A, Garcia-Vicente F, Sevillano D, Martin de Vidales C, Ferrer C,
Torres JJ, et al. Is hormone therapy a protective factor for late hematuria
after high-dose radiotherapy in prostate cancer? Urology. 2008;72:1130–4.
11. Devisetty K, Zorn KC, Katz MH, Jani AB, Liauw SL. External beam radiation
therapy after transurethral resection of the prostate: a report on acute and
late genitourinary toxicity. Int J Radiat Oncol Biol Phys. 2010;77:1060–5.
12. Sandhu AS, Zelefsky MJ, Lee HJ, Lombardi D, Fuks Z, Leibel SA. Long-term
urinary toxicity after 3-dimensional conformal radiotherapy for prostate
cancer in patients with prior history of transurethral resection. Int J Radiat
Oncol Biol Phys. 2000;48:643–7.
13. Choe KS, Jani AB, Liauw SL. External beam radiotherapy for prostate cancer
patients on anticoagulation therapy: how significant is the bleeding
toxicity? Int J Radiat Oncol Biol Phys. 2010;76:755–60.
Gurka et al. Radiation Oncology  (2015) 10:44 Page 7 of 714. Fowler JF. The radiobiology of prostate cancer including new aspects of
fractionated radiotherapy. Acta Oncol. 2005;44:265–76.
15. Demanes DJ, Martinez AA, Ghilezan M, Hill DR, Schour L, Brandt D, et al.
High-dose-rate monotherapy: safe and effective brachytherapy for patients
with localized prostate cancer. Int J Radiat Oncol Biol Phys. 2011;81:1286–92.
16. King CR, Collins S, Fuller D, Wang PC, Kupelian P, Steinberg M, et al.
Health-related quality of life after stereotactic body radiation therapy for
localized prostate cancer: results from a multi-institutional consortium of
prospective trials. Int J Radiat Oncol Biol Phys. 2013;87:939–45.
17. King CR, Freeman D, Kaplan I, Fuller D, Bolzicco G, Collins S, et al.
Stereotactic body radiotherapy for localized prostate cancer: pooled analysis
from a multi-institutional consortium of prospective phase II trials.
Radiother Oncol. 2013;109:217–21.
18. Chen LN, Suy S, Uhm S, Oermann EK, Ju AW, Chen V, et al. Stereotactic
body radiation therapy (SBRT) for clinically localized prostate cancer:
the Georgetown University experience. Radiat Oncol. 2013;8:58.
19. Lei S, Piel N, Oermann EK, Chen V, Ju AW, Dahal KN, et al. Six-dimensional
correction of intra-fractional prostate motion with CyberKnife stereotactic
body radiation therapy. Front Oncol. 2011;1:48.
20. Xie Y, Djajaputra D, King CR, Hossain S, Ma L, Xing L. Intrafractional motion
of the prostate during hypofractionated radiotherapy. Int J Radiat Oncol Biol
Phys. 2008;72:236–46.
21. Vainshtein J, Abu-Isa E, Olson KB, Ray ME, Sandler HM, Normolle D, et al.
Randomized phase II trial of urethral sparing intensity modulated radiation
therapy in low-risk prostate cancer: implications for focal therapy.
Radiat Oncol. 2012;7:82.
22. Wei JT, Dunn RL, Litwin MS, Sandler HM, Sanda MG. Development and
validation of the expanded prostate cancer index composite (EPIC) for
comprehensive assessment of health-related quality of life in men with
prostate cancer. Urology. 2000;56:899–905.
23. Barnett GC, De Meerleer G, Gulliford SL, Sydes MR, Elliott RM, Dearnaley DP.
The impact of clinical factors on the development of late radiation toxicity:
results from the Medical Research Council RT01 trial (ISRCTN47772397).
Clin Oncol. 2011;23:613–24.
24. De Langhe S, De Meerleer G, De Ruyck K, Ost P, Fonteyne V, De Neve W,
et al. Integrated models for the prediction of late genitourinary complaints
after high-dose intensity modulated radiotherapy for prostate cancer:
Making informed decisions. Radiotherapy and oncology. 2014
[Epub ahead of print]
25. Barker Jr J, Wallner K, Merrick G. Gross hematuria after prostate
brachytherapy. Urology. 2003;61:408–11.
26. Mohammed N, Kestin L, Ghilezan M, Krauss D, Vicini F, Brabbins D, et al.
Comparison of acute and late toxicities for three modern high-dose
radiation treatment techniques for localized prostate cancer. Int J Radiat
Oncol Biol Phys. 2012;82:204–12.
27. Grise P, Thurman S. Urinary incontinence following treatment of localized
prostate cancer. Cancer Control. 2001;8:532–9.
28. Ishiyama H, Hirayama T, Jhaveri P, Satoh T, Paulino AC, Xu B, et al. Is there
an increase in genitourinary toxicity in patients treated with transurethral
resection of the prostate and radiotherapy?: a systematic review. Am J Clin
Oncol. 2014;37:297–304.
29. Heemsbergen WD, Al-Mamgani A, Witte MG, van Herk M, Pos FJ, Lebesque
JV. Urinary obstruction in prostate cancer patients from the Dutch trial
(68 Gy vs. 78 Gy): relationships with local dose, acute effects, and baseline
characteristics. Int J Radiat Oncol Biol Phys. 2010;78:19–25.
30. Seymore CH, el-Mahdi AM, Schellhammer PF. The effect of prior transurethral
resection of the prostate on post radiation urethral strictures and bladder neck
contractures. Int J Radiat Oncol Biol Phys. 1986;12:1597–600.
31. Freeman DE, King CR. Stereotactic body radiotherapy for low-risk prostate
cancer: five-year outcomes. Radiat Oncol. 2011;6:3.
32. Katz A, Kang J. Stereotactic body radiotherapy with or without external
beam radiation as treatment for organ confined high-risk prostate carcinoma:
a six year study. Radiat Oncol. 2014;9:1.
33. Spratt DE, Pei X, Yamada J, Kollmeier MA, Cox B, Zelefsky MJ. Long-term
survival and toxicity in patients treated with high-dose intensity modulated
radiation therapy for localized prostate cancer. Int J Radiat Oncol Biol Phys.
2013;85:686–92.
34. ACR Appropriateness Criteria® External Beam Radiation Therapy Treatment
Planning for Clinically Localized Prostate Cancer. [https://acsearch.acr.org/
docs/69396/Narrative/].35. Gluck I, Vineberg KA, Ten Haken RK, Sandler HM. Evaluating the
relationships between rectal normal tissue complication probability and the
portion of seminal vesicles included in the clinical target volume in
intensity-modulated radiotherapy for prostate cancer. Int J Radiat Oncol Biol
Phys. 2009;73:334–40.
36. Sanda MG, Dunn RL, Michalski J, Sandler HM, Northouse L, Hembroff L, et al.
Quality of life and satisfaction with outcome among prostate-cancer survivors.
N Engl J Med. 2008;358:1250–61.
37. Litwin MS, Gore JL, Kwan L, Brandeis JM, Lee SP, Withers HR, et al. Quality of
life after surgery, external beam irradiation, or brachytherapy for early-stage
prostate cancer. Cancer. 2007;109:2239–47.
38. Gore JL, Gollapudi K, Bergman J, Kwan L, Krupski TL, Litwin MS. Correlates of
bother following treatment for clinically localized prostate cancer. J Urol.
2010;184:1309–15.
39. Hoppe BS, Michalski JM, Mendenhall NP, Morris CG, Henderson RH,
Nichols RC, et al. Comparative effectiveness study of patient-reported
outcomes after proton therapy or intensity-modulated radiotherapy for
prostate cancer. Cancer. 2014;120:1076–82.
40. Zelefsky MJ, Housman DM, Pei X, Alicikus Z, Magsanoc JM, Dauer LT, et al.
Incidence of secondary cancer development after high-dose
intensity-modulated radiotherapy and image-guided brachytherapy for
the treatment of localized prostate cancer. Int J Radiat Oncol Biol Phys.
2012;83:953–9.
41. Leapman MS, Stock RG, Stone NN, Hall SJ. Findings at cystoscopy
performed for cause after prostate brachytherapy. Urology. 2014;83:1350–5.
42. Litwin MS, McGuigan KA. Accuracy of recall in health-related quality-of-life
assessment among men treated for prostate cancer. J Clin Oncol.
1999;17:2882–8.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
